Arcutis Biotherapeutics (ARQT) EBITDA Margin (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly EBITDA Margin of 8.62% for Q1 2026, up 2980.0% year-over-year from 0.28% in Q1 2025, and down 160.74% quarter-over-quarter from 14.2% in Q4 2025.
Powered by 
Analysis
Arcutis Biotherapeutics (ARQT) EBITDA Margin (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' EBITDA Margin history runs 5 years deep, the most recent figure standing at 8.62% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 2980.0% year-over-year to 8.62%; the TTM figure through Mar 2026 stood at 0.77% (up 5886.0% YoY), while the FY2025 annual figure was 3.25%, up 7384.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 8.62%, down from 14.2% in the prior quarter.
- The five-year high for EBITDA Margin was 14.2% in Q4 2025, with the low at 14448.0% in Q3 2022.
- The 5-year median for EBITDA Margin is 96.84% (2023), against an average of 1439.08%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin soared 1435116 bps in 2023, then surged 955 bps in 2024.
- Arcutis Biotherapeutics' EBITDA Margin stood at 2310.84% in 2022, then surged by 94 bps to 139.19% in 2023, then jumped by 92 bps to 11.0% in 2024, then soared by 229 bps to 14.2% in 2025, then slumped by 161 bps to 8.62% in 2026.
- Business Quant data shows ARQT's EBITDA Margin at 8.62% in Q1 2026, 14.2% in Q4 2025, and 8.59% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn | 12.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.65% |
| Mar 31, 2026 | -8.62% |
| Dec 31, 2025 | 14.20% |
| Sep 30, 2025 | 8.59% |
| Jun 30, 2025 | -17.93% |
| Mar 31, 2025 | -37.25% |
| Dec 31, 2024 | -10.70% |
| Sep 30, 2024 | -87.29% |
| Jun 30, 2024 | -162.28% |
| Mar 31, 2024 | -63.79% |
| Dec 31, 2023 | -452.23% |
| Sep 30, 2023 | -96.84% |
| Jun 30, 2023 | -1,286.38% |
| Mar 31, 2023 | -2,742.36% |
| Dec 31, 2022 | -2,310.84% |
| Sep 30, 2022 | -14,448.00% |